Cervical Pathology Following HPV Vaccination in Greece: A 10-year HeCPA Observational Cohort Study.
Adult
Cervix Uteri
/ pathology
Cohort Studies
Colposcopy
Cytodiagnosis
Female
Greece
/ epidemiology
Humans
Papillomaviridae
/ immunology
Papillomavirus Infections
/ complications
Papillomavirus Vaccines
/ administration & dosage
Public Health Surveillance
Uterine Cervical Neoplasms
/ epidemiology
Vaccination
HPV
vaccination
vaccine
Journal
In vivo (Athens, Greece)
ISSN: 1791-7549
Titre abrégé: In Vivo
Pays: Greece
ID NLM: 8806809
Informations de publication
Date de publication:
Historique:
received:
28
01
2020
revised:
25
02
2020
accepted:
04
03
2020
entrez:
2
5
2020
pubmed:
2
5
2020
medline:
11
2
2021
Statut:
ppublish
Résumé
In Greece the population-level impact of HPV vaccination is unknown due to lack of official registries. This study presents in a pragmatic frame the comparison of cervical pathology data between HPV-vaccinated and unvaccinated women referred for colposcopy. This is an observational prospective cohort study performed in 7 academic Obstetrics and Gynaecology Departments across Greece between 2009-2019. Cases were women that had completed HPV vaccination before coitarche and were referred for colposcopy due to abnormal cytology. For each vaccinated woman an unvaccinated matched control was selected. A total of 849 women who had been vaccinated before coitarche and 849 unvaccinated controls were recruited. The combination of cytological, colposcopic and molecular findings necessitated treatment in only a single case among vaccinated (0.1%) and in 8.4% among unvaccinated. HPV vaccination at a proper age can markedly reduce development of severe cervical precancers and consequently the need for treatment, as well as their long-term related obstetrical morbidity.
Sections du résumé
BACKGROUND
BACKGROUND
In Greece the population-level impact of HPV vaccination is unknown due to lack of official registries. This study presents in a pragmatic frame the comparison of cervical pathology data between HPV-vaccinated and unvaccinated women referred for colposcopy.
PATIENTS AND METHODS
METHODS
This is an observational prospective cohort study performed in 7 academic Obstetrics and Gynaecology Departments across Greece between 2009-2019. Cases were women that had completed HPV vaccination before coitarche and were referred for colposcopy due to abnormal cytology. For each vaccinated woman an unvaccinated matched control was selected.
RESULTS
RESULTS
A total of 849 women who had been vaccinated before coitarche and 849 unvaccinated controls were recruited. The combination of cytological, colposcopic and molecular findings necessitated treatment in only a single case among vaccinated (0.1%) and in 8.4% among unvaccinated.
CONCLUSION
CONCLUSIONS
HPV vaccination at a proper age can markedly reduce development of severe cervical precancers and consequently the need for treatment, as well as their long-term related obstetrical morbidity.
Identifiants
pubmed: 32354944
pii: 34/3/1445
doi: 10.21873/invivo.11927
pmc: PMC7279786
doi:
Substances chimiques
Papillomavirus Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1445-1449Informations de copyright
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Références
BMJ. 2019 Apr 3;365:l1161
pubmed: 30944092
Ann Oncol. 2020 Feb;31(2):213-227
pubmed: 31959338
Lancet. 1987 May 30;1(8544):1247-9
pubmed: 2884378
Int J Cancer. 2012 Jul 1;131(1):106-16
pubmed: 21858807
Infect Dis Obstet Gynecol. 2006;2006 Suppl:40470
pubmed: 16967912
PLoS Med. 2008 Jun 17;5(6):e132
pubmed: 18563963
Lancet Public Health. 2019 Jan;4(1):e19-e27
pubmed: 30291040
Lancet Glob Health. 2016 Jul;4(7):e453-63
pubmed: 27340003
BMJ. 2014 Oct 28;349:g6192
pubmed: 25352501
Anticancer Res. 2018 May;38(5):3079-3084
pubmed: 29715143
Anticancer Res. 2012 Sep;32(9):4141-5
pubmed: 22993375
Cochrane Database Syst Rev. 2018 May 09;5:CD009069
pubmed: 29740819
Lancet Oncol. 2017 Dec;18(12):1665-1679
pubmed: 29126708
Cochrane Database Syst Rev. 2015 Sep 29;(9):CD008478
pubmed: 26417855
Anticancer Res. 2001 Jul-Aug;21(4B):3097-9
pubmed: 11712817
Anticancer Res. 2010 Jun;30(6):2319-23
pubmed: 20651386
BMJ. 2018 Feb 27;360:k499
pubmed: 29487049
J Infect Dis. 2011 Aug 1;204(3):377-84
pubmed: 21742836
Gynecol Oncol. 2013 Aug;130(2):264-8
pubmed: 23623831
Int J Cancer. 1997 Apr 10;71(2):159-65
pubmed: 9139836
Cochrane Database Syst Rev. 2013 Dec 04;(12):CD001318
pubmed: 24302546
Virchows Arch. 2018 Apr;472(4):677-682
pubmed: 29302754
BMJ. 2008 Sep 18;337:a1284
pubmed: 18801868
BMJ Open. 2019 Oct 21;9(10):e028009
pubmed: 31636110
Drug Saf. 2018 Apr;41(4):329-346
pubmed: 29280070
J Infect Dis. 2013 Jun 1;207(11):1753-63
pubmed: 23242542
BMJ Open. 2019 Aug 2;9(8):e028008
pubmed: 31377697
JAMA. 2016 Dec 13;316(22):2411-2421
pubmed: 27893068
Cochrane Database Syst Rev. 2017 Nov 02;11:CD012847
pubmed: 29095502
BMJ. 2016 Jul 28;354:i3633
pubmed: 27469988
Lancet. 2006 Feb 11;367(9509):489-98
pubmed: 16473126
Gynecol Oncol. 2018 Nov;151(2):229-234
pubmed: 30197061
Lancet. 2019 Aug 10;394(10197):497-509
pubmed: 31255301